JP2021529796A5 - - Google Patents

Info

Publication number
JP2021529796A5
JP2021529796A5 JP2021500040A JP2021500040A JP2021529796A5 JP 2021529796 A5 JP2021529796 A5 JP 2021529796A5 JP 2021500040 A JP2021500040 A JP 2021500040A JP 2021500040 A JP2021500040 A JP 2021500040A JP 2021529796 A5 JP2021529796 A5 JP 2021529796A5
Authority
JP
Japan
Prior art keywords
fzd
binding region
wnt
lrp5
binding
Prior art date
Application number
JP2021500040A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020010308A5 (https=
JP2021529796A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/040687 external-priority patent/WO2020010308A1/en
Publication of JP2021529796A publication Critical patent/JP2021529796A/ja
Publication of JPWO2020010308A5 publication Critical patent/JPWO2020010308A5/ja
Publication of JP2021529796A5 publication Critical patent/JP2021529796A5/ja
Priority to JP2023186681A priority Critical patent/JP2024001292A/ja
Pending legal-status Critical Current

Links

JP2021500040A 2018-07-05 2019-07-05 多特異性Wnt代替分子及びその使用 Pending JP2021529796A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023186681A JP2024001292A (ja) 2018-07-05 2023-10-31 多特異性Wnt代替分子及びその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862694339P 2018-07-05 2018-07-05
US62/694,339 2018-07-05
US201862782122P 2018-12-19 2018-12-19
US62/782,122 2018-12-19
US201962797772P 2019-01-28 2019-01-28
US62/797,772 2019-01-28
PCT/US2019/040687 WO2020010308A1 (en) 2018-07-05 2019-07-05 Multi-specific wnt surrogate molecules and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023186681A Division JP2024001292A (ja) 2018-07-05 2023-10-31 多特異性Wnt代替分子及びその使用

Publications (3)

Publication Number Publication Date
JP2021529796A JP2021529796A (ja) 2021-11-04
JPWO2020010308A5 JPWO2020010308A5 (https=) 2022-07-12
JP2021529796A5 true JP2021529796A5 (https=) 2022-07-12

Family

ID=69059929

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021500040A Pending JP2021529796A (ja) 2018-07-05 2019-07-05 多特異性Wnt代替分子及びその使用
JP2023186681A Pending JP2024001292A (ja) 2018-07-05 2023-10-31 多特異性Wnt代替分子及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023186681A Pending JP2024001292A (ja) 2018-07-05 2023-10-31 多特異性Wnt代替分子及びその使用

Country Status (10)

Country Link
US (1) US20210292422A1 (https=)
EP (2) EP4733325A2 (https=)
JP (2) JP2021529796A (https=)
CN (2) CN120623353A (https=)
AU (1) AU2019297522B2 (https=)
CA (1) CA3104526A1 (https=)
DK (1) DK3820906T3 (https=)
ES (1) ES3058239T3 (https=)
PL (1) PL3820906T3 (https=)
WO (1) WO2020010308A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7305543B2 (ja) 2017-01-26 2023-07-10 スロゼン オペレーティング, インコーポレイテッド 組織特異的Wntシグナル増強分子およびその使用
CN111699003B (zh) * 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
CN111655729B (zh) * 2017-12-19 2023-10-20 瑟罗泽恩奥普瑞汀公司 抗卷曲蛋白抗体和使用方法
EP3732201A4 (en) 2017-12-19 2022-04-20 Surrozen Operating, Inc. WNT SURROGATES AND THEIR USES
US20210032352A1 (en) * 2018-02-14 2021-02-04 Antera Therapeutics Inc. Multivalent Binding Molecules Activating WNT Signaling and Uses Thereof
JP2021530223A (ja) 2018-07-09 2021-11-11 スロゼン, インコーポレイテッド 組織特異性Wntシグナル増強分子及びその使用
AU2020300618A1 (en) * 2019-07-02 2022-01-27 Surrozen Operating, Inc. Monospecific anti-frizzled antibodies and methods of use
CN115427446A (zh) * 2020-02-24 2022-12-02 瑟罗泽恩奥普瑞汀公司 Wnt超级激动剂
TW202233656A (zh) 2020-11-16 2022-09-01 美商蘇羅森營運公司 肝特異性wnt訊號增強分子及其用途
WO2022130342A1 (en) * 2020-12-18 2022-06-23 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
WO2023250402A2 (en) * 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
WO2023130055A2 (en) * 2021-12-31 2023-07-06 Surrozen Operating, Inc. Wnt receptor-specific compound and method relating thereto
AU2024279826A1 (en) * 2023-05-29 2026-01-08 Surrozen Operating, Inc. Wnt surrogate agents and methods for lacrimal gland regeneration

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20030044409A1 (en) 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス,インコーポレーテッド 変異型Fc領域を含む抗体の同定および作製ならびにその利用法
CA2548817A1 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
PL1776384T3 (pl) 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
DE102004050620A1 (de) 2004-10-13 2006-04-20 Eberhard-Karls-Universität Tübingen Monoklonaler Antikörper gegen Frizzled-Rezeptoren
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
EP1810035A4 (en) 2004-11-10 2010-03-17 Macrogenics Inc GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
CA2602663A1 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc variants with optimized properties
DE102005035568A1 (de) 2005-07-25 2007-02-01 M-Phasys Gmbh Frizzled 9 als Biomarker für Substrukturen des humanen Gehirns
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CN101573383B (zh) 2006-06-21 2015-05-13 肿瘤疗法科学股份有限公司 靶向肿瘤的针对卷曲同源物10的单克隆抗体及其用途
KR20100091170A (ko) * 2007-11-02 2010-08-18 노파르티스 아게 저밀도-지단백질 수용체-관련 단백질 6 (lrp6)을 조정하기 위한 분자 및 방법
CA2705923A1 (en) 2007-11-16 2009-05-22 Nuvelo, Inc. Antibodies to lrp6
CN103002911B (zh) 2008-09-26 2015-08-26 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
ES2579909T3 (es) 2009-02-03 2016-08-17 Koninklijke Nederlandse Akademie Van Wetenschappen Medio de cultivo para células madre epiteliales y organoides que comprenden dichas células madre
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
AR080795A1 (es) 2010-03-24 2012-05-09 Genentech Inc Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
EP3033356B1 (en) 2013-08-14 2020-01-15 Sachdev Sidhu Antibodies against frizzled proteins and methods of use thereof
GB2519786A (en) * 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
US11142577B2 (en) * 2014-09-12 2021-10-12 The Board Of Trustees Of The Leland Stanford Junior University WNT signaling agonist molecules
WO2016205566A1 (en) 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
US10766962B2 (en) 2015-06-16 2020-09-08 The Regents Of The University Of California FZD7 specific antibodies and vaccines to treat cancer and control stem cell function
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
KR102802241B1 (ko) * 2015-12-04 2025-05-07 베링거 인겔하임 인터내셔날 게엠베하 종양 세포에서 wnt 신호 전달을 길항하는 바이파라토픽 폴리펩타이드
US10919968B2 (en) 2016-01-29 2021-02-16 Modmab Therapeutics Corporation Frizzled5 protein-binding agents
RU2767329C2 (ru) 2016-02-06 2022-03-17 Эпимаб Биотерапьютикс, Инк. Иммуноглобулин с тандемными fab-фрагментами и варианты его применения
EP3732201A4 (en) * 2017-12-19 2022-04-20 Surrozen Operating, Inc. WNT SURROGATES AND THEIR USES
US20210032352A1 (en) * 2018-02-14 2021-02-04 Antera Therapeutics Inc. Multivalent Binding Molecules Activating WNT Signaling and Uses Thereof

Similar Documents

Publication Publication Date Title
JP2021529796A5 (https=)
JP2021508247A5 (https=)
JP2021508683A5 (https=)
CN111655729B (zh) 抗卷曲蛋白抗体和使用方法
CN112566940B (zh) 多特异性wnt替代分子和其用途
JPWO2020010308A5 (https=)
CN118271444A (zh) Wnt替代分子和其用途
JP6647208B2 (ja) 抗il−17抗体、その生産および使用のための方法
JP7317016B2 (ja) 抗lrp5/6抗体及び使用方法
JP2017522888A (ja) 多重特異性抗体
JP2021523913A5 (https=)
JP2023504699A (ja) 治療および診断のための新規な分子
JP2010526028A5 (https=)
TW201631153A (zh) 具有替代血液凝固第viii因子之功能的多重專一性抗原結合分子
RU2009133789A (ru) Способы лечения глазных болезней
JP2026016376A5 (https=)
JP2022553830A (ja) N末端scFv多重特異性結合分子
CA2935285A1 (en) Anti-pcsk9-glp-1 fusions and methods for use
WO2019195313A1 (en) Anti-vegf antagonist and pedf agonist constructs and uses thereof
JPWO2019126399A5 (https=)
JP2025134864A5 (https=)
CN107074963A (zh) 抑制血管内皮脂肪酶的酶活性的人源化单克隆抗体
JPWO2019126401A5 (https=)
WO2011038575A1 (en) Novel antibody treatment
JP2023535840A (ja) 抗原結合タンパク質